SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as a significant validation of its platform technology across potential new disease areas. The community is actively discussing the potential for upfront payments, substantial milestones, and royalties, while also looking for further partnerships, particularly for its advanced COVID-Flu combination vaccine. This recent strategic move, alongside the company's strengthened financial position, is generating optimism about future growth despite ongoing activist investor pressure.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending as discussions erupt over former President Trump's threats of new tariffs on European nations, stemming from their stance on Greenland and his apparent frustrations regarding the Nobel Peace Prize. This has ignited heated debate among the community, with many expressing concern over potential market instability and strained international relations, while supporters view these actions as beneficial for "America First" economic policies.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing heightened volatility as President Trump's escalating tariff threats against NATO allies, particularly concerning Greenland, spark widespread geopolitical uncertainty. Community sentiment is sharply divided, with some anticipating a deeper market correction while others view the current downturn as a 'buy the dip' opportunity amidst global bond market concerns and a notable rise in precious metal prices. Investors are closely monitoring a potential Supreme Court ruling on tariffs as a key market mover.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing significant volatility and trending discussions following a critical report alleging financial misconduct, compounded by broader weakness in the tech sector. While many in the community are dismissing the report as rehashed FUD and market manipulation, bulls are highlighting the company's strong AI-powered ad platform and anticipated robust Q4 earnings. This has fueled a sharp debate between those buying the dip and bears reacting to the serious claims, driving notable price swings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending ahead of its upcoming earnings, with community focus on its recent all-cash bid for Warner Bros. Discovery assets and a prominent figure's bond purchases. Bulls anticipate a significant rebound for the perceived oversold stock, highlighting its "tariff-proof" nature amidst a broader red market. Bears, however, warn of further downside, viewing the deal as a potential drag and suggesting market volatility around the report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Goldman Sachs began coverage of Stellantis with a ‘Neutral’ rating and said it shares the “attractive value” seen across undervalued premium automakers.</li><li>The firm highlighted sector pressures from Chinese competition, electric-vehicle momentum and tightening European Union rules.</li><li>BMW, Mercedes-Benz, Renault, Ferrari, Volkswagen, Porsche AG and Aston Martin Lagonda were all initiated with varying upside or downside expectations.</li></ul>Stellantis&nbsp;NV offers the same “attractive value” Goldman Sachs sees across Europe’s premium automakers, the bank’s research arm said as it initiated coverage of several carmakers during what it described as “tumultuous times” for the sector. Goldman began coverage of Stellantis with a ‘Neutral’ rating and a $10 price target, implying a 1.3% upside from the last close. The firm said Stellantis shares its valuation appeal, identifying the most undervalued areas of the European auto industry.<h2 class="st-heading-2">Goldman Flags Market Pressure&nbsp;</h2>Goldman said European automakers face growing pressure as Chinese manufacturers expand globally and battery electric vehicle momentum accelerates. The firm added that European Union tariffs, currency swings, and tightening emissions rules are adding further strain. Goldman noted that BMW, Mercedes, Volkswagen and Renault now trade at negative industrial stub valuations, which it called “premature,” and said the premium segment remains the most undervalued part of the market.<h2 class="st-heading-2">Automakers Goldman Sees As Attractive Value Opportunities</h2>Goldman highlighted several automakers that it believes offer meaningful upside. The company initiated BMW with a ‘Buy’ rating and a 112 euro price target, implying a 32% upside. Mercedes-Benz was also initiated with a ‘Buy’ rating and a 74 euro price target, representing a 30% upside. Goldman said it likes both BMW and Mercedes-Benz for their “healthy” balance sheets and “shareholder-friendly” capital allocation frameworks.The bank initiated Ferrari with a ‘Buy’ rating and a $454 price target, giving the stock a 35% upside. Goldman said Ferrari’s higher-priced Special Series volumes support stronger selling prices and growth.Goldman also said Renault offers the same “attractive value” seen across premium automakers. The firm began coverage with a ‘Neutral’ rating and a 36-euro price target, implying a 5% upside.&nbsp;<h2 class="st-heading-2">Automakers Goldman Views More Cautiously</h2>Goldman initiated coverage of Volkswagen with a ‘Neutral’ rating and a 106-euro price target, giving it a 12% upside. Porsche AG was also initiated at a ‘Neutral’ rating with a 46 euro price target, representing a 29% upside.Aston Martin Lagonda received a ‘Neutral’ rating and a 61-pound price target, which reflects a 1% downside. The bank’s research arm highlighted structural concerns over Aston Martin’s balance sheet.<h2 class="st-heading-2">Stocktwits Traders Back Stellantis, BMW, Renault&nbsp;</h2>On Stocktwits, automakers including Stellantis, BMW, Mercedes-Benz, and Renault all saw ‘bullish’ sentiment, though message volume was ‘high’ for Stellantis, ‘normal’ for BMW and Renault, and ‘low’ for Mercedes-Benz.Porsche AG and Aston Martin Lagonda each recorded ‘neutral’ sentiment, with Porsche seeing ‘low’ message volume while Aston Martin registered ‘normal’ activity. Among the outliers, Ferrari drew ‘bearish’ sentiment on ‘low’ message volume, while Volkswagen saw ‘extremely bearish’ sentiment, also amid ‘low’ message volume.So far this year, performance across U.S.-listed European automakers has been mixed.&nbsp;<a href="https://stocktwits.com/symbol/STLA">Stellantis</a> is down 19%, Renault is down 15%, Ferrari is down 8%, and Aston Martin Lagonda is down 38%. Meanwhile, several peers have gained ground, with&nbsp;<a href="https://stocktwits.com/symbol/BMWYY">BMW</a> up 25%,&nbsp;<a href="https://stocktwits.com/symbol/MBGAF">Mercedes-Benz</a> up 26%,&nbsp;<a href="https://stocktwits.com/symbol/VLKAY">Volkswagen</a> up 26% and&nbsp;<a href="https://stocktwits.com/symbol/POAHY">Porsche</a> up 14% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of the historical FIAT plant in Turin, Italy. (Photo by Mauro Ujetto/NurPhoto via Getty Images)

Stellantis Stock Joins Undervalued Premium Peers In Goldman’s ‘Attractive Value’ Call Despite Sector Turbulence

The firm highlighted sector pressures from Chinese competition, electric-vehicle momentum and tightening European Union rules.

Equity

Aston Martin shares slid more than 3% in London on Wednesday after the British luxury carmaker cut its 2025 profit outlook, blaming "evolving and disruptive" U.S. auto tariffs.Under a U.S.-UK trade deal implemented in May, the first 100,000 UK car imports are subject to a 10% tariff, while any shipments exceeding that threshold are subject to a 27.5% duty. Aston Martin stated that the quota system is hindering its ability to forecast results and could impact margins into 2026."We continue to actively engage the UK government to urge them to improve the quota mechanism to ensure fair access for the whole UK car industry to the 10% rate on an ongoing basis," CEO Adrian Hallmark said in a statement.The company now expects its gross margin this year to be broadly in line with last year's 37%, which is below its prior target of 40%. Adjusted earnings before interest and tax (EBIT) may no longer turn positive in 2025, instead moving toward breakeven.For the latest quarter, Aston Martin posted an adjusted operating loss of £57 million&nbsp;($76.16 million) versus a £42.7 million loss a year ago. Revenue fell 34% to £220.5 million, below the consensus of £270 million. Wholesale volumes dropped 8% to 972 units, while retail deliveries outpaced wholesales by over 40%.The broader UK auto industry is also reeling, with output&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/06/27/trump-tariffs-uk-car-and-vehicle-output-falls-to-76-year-low-in-may.html#:~:text=The%20U.K.'s%20new%20car,level%20since%201949%20in%20May.">reportedly</a> at its lowest level since 1949, as exports have paused amid Trump's tariffs.&nbsp;Aston Martin’s London-listed shares are down 26% year-to-date, while its over-the-counter stock in the U.S. has fallen nearly 14%.On Stocktwits, retail sentiment toward Aston Martin remains 'bearish' amid 'high' message volume late Tuesday.(£1 = $1.34)For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/li-auto-just-launched-its-first-electric-suv-here-s-why-investors-are-already-backing-off/choQ86IR5yy">Li Auto Just Launched Its First Electric SUV: Here’s Why Investors Are Already Backing Off</a>

An Aston Martin Vantage is displayed in the Mayfair showroom on Park Lane on January 09, 2025 in London, England. (Photo by John Keeble/Getty Images)

Aston Martin Wants UK To Tweak Trump Trade Deal After Cutting 2025 Targets On 'Disruptive' Auto Tariffs

Adjusted earnings before interest and tax (EBIT) may no longer turn positive in 2025, the company said, instead moving toward breakeven.

Aston Martin Lagonda Global Holdings Plc engages in the business of designing, creating, and exporting cars. Its current models include the Vantage, dB12, Vanquish, DBX707, Valhalla, Valkyrie, Valour, Valiant amd AMR25 F1. The company was founded by Robert Bamford and Lionel Martin on January 15, 1913 and is headquartered in Warwick, the United Kingdom.

Current Price	$0.812
Prev Close	$0.8366
Open	$0.812
Dividend Yield	0.00%
50-Day Moving Average	$0.8315
Beta	0.30
Avg. Volume	16,205.55
PE Ratio	-2.15

52-Week High	$1.63
52-Week Low	$0.7383
Market Capitalization	$822.12M
EPS (Annual)	-$0.4966
Price to Book	0.89
Revenue Per Employee	$673,295.71
Enterprise Value/EBITDA	N/A

AMGDF
Aston Martin Lagonda Global Holdings Plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMGDF News

AMGDFAston Martin Lagonda Global Holdings Plc